8-K: Dentsply Sirona Reports Mixed Q1 2024 Results, Maintains Full-Year Outlook

Dentsply Sirona's first quarter 2024 results show a slight sales decrease and mixed performance across segments, while the company maintains its full-year outlook but expects to trend towards the lower end of guidance.

Summary

• Dentsply Sirona reported first quarter 2024 net sales of $953 million, a decrease of 2.6% compared to the same period last year, with organic sales declining by 1.9%.
• The company's GAAP net income was $18 million, or $0.09 per share, a significant improvement from a net loss of $19 million, or $0.09 per share loss, in the first quarter of 2023.
• Adjusted earnings per diluted share were $0.42, up from $0.39 in the first quarter of 2023.
• The adjusted EBITDA margin was 16.8%, compared to 16.5% in the prior year.
• Dentsply Sirona is maintaining its full-year 2024 outlook for organic sales growth of flat to up 1.5% and adjusted EPS of $2.00 to $2.10, but expects to trend towards the low end of these ranges.
• The company anticipates repurchasing up to $150 million of its common stock in the second quarter of 2024.
• The company has revised its full year reported sales guidance to $3.91 billion to $3.97 billion due to a $50 million foreign currency headwind.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company showed improvement in net income and some growth areas, the overall sales decline and the expectation to trend towards the low end of guidance temper the positive aspects. The maintained full-year outlook provides some stability, but the headwinds are concerning.

Positives

• The company's net income improved significantly, moving from a loss of $19 million in Q1 2023 to a profit of $18 million in Q1 2024.
• Adjusted earnings per share increased to $0.42 from $0.39 year-over-year.
• The company saw strong growth in specific areas, including over 50% growth in China, double-digit growth in global aligners, and mid-single digit growth in Wellspect Healthcare.
• Operating cash flow improved to $25 million, compared to a loss of $21 million in the prior year, due to lower inventory build and improved cash collections.

Negatives

• Net sales decreased by 2.6% year-over-year, with organic sales declining by 1.9%.
• The company's sales were softer than anticipated due to continued lower demand for imaging equipment.
• The company expects to trend towards the low end of its full-year outlook for both organic sales and adjusted EPS.
• The company has revised its full year reported sales guidance to $3.91 billion to $3.97 billion due to a $50 million foreign currency headwind.

Risks

• The macroeconomic environment remains uncertain, which could impact future performance.
• Continued lower demand for imaging equipment is a concern.
• The company's full-year outlook is trending towards the low end of the provided ranges.
• Foreign currency translation headwinds are impacting reported sales.

Future Outlook

The company is maintaining its 2024 outlook for organic sales growth of flat to up 1.5% and adjusted EPS of $2.00 to $2.10, but expects to trend towards the low end of these ranges. The company has revised its full year reported sales guidance to $3.91 billion to $3.97 billion due to a $50 million foreign currency headwind.

Management Comments

• Simon Campion, President and Chief Executive Officer, stated that first quarter sales were softer than anticipated due to lower demand for imaging equipment.
• Simon Campion noted bright spots in the business, including over 50% growth in China, double-digit growth in global aligners, and mid-single digit growth in Wellspect Healthcare.
• Management believes that the company's transformation will position it to deliver long-term sustainable performance.

Industry Context

The dental industry is experiencing mixed trends, with some segments showing strong growth while others face headwinds. Dentsply Sirona's results reflect these trends, with strong performance in aligners and China, but weakness in imaging equipment. The company's focus on strategic initiatives and transformation is aimed at navigating these challenges and positioning it for long-term growth.

Comparison to Industry Standards

• Dentsply Sirona's organic sales decline of 1.9% is below the average growth rate for the dental equipment industry, which has seen modest growth in recent quarters.
• Competitors such as Align Technology have reported stronger growth in the aligner segment, indicating that Dentsply Sirona's double-digit growth, while positive, may not be leading the market.
• The company's adjusted EBITDA margin of 16.8% is comparable to other large dental equipment manufacturers, but there is room for improvement to reach the higher end of the industry range.
• Companies like Straumann have shown stronger performance in the implant segment, suggesting that Dentsply Sirona's 5.6% organic growth in Orthodontic and Implant Solutions is moderate compared to industry leaders.

Stakeholder Impact

• Shareholders may be concerned about the sales decline and the company trending towards the low end of its guidance.
• Employees may be affected by the company's restructuring and transformation efforts.
• Customers may experience changes in product offerings and services as the company implements its strategic initiatives.
• Suppliers may be impacted by changes in the company's procurement and supply chain strategies.

Next Steps

• The company will continue to focus on its strategic initiatives and transformation.
• Dentsply Sirona plans to repurchase up to $150 million of its common stock in Q2 2024.
• The company will host an investor conference call and live webcast on May 2, 2024, at 8:30 am ET.

Key Dates

Keywords

Dentsply Sirona, Dental Products, Financial Results, Q1 2024, Earnings, Net Sales, Organic Sales, Adjusted EPS, EBITDA, Stock Repurchase, Dental Technology, Healthcare